Saltar al contenido
Merck

Breast cancer colonization by Fusobacterium nucleatum accelerates tumor growth and metastatic progression.

Nature communications (2020-06-28)
Lishay Parhi, Tamar Alon-Maimon, Asaf Sol, Deborah Nejman, Amjad Shhadeh, Tanya Fainsod-Levi, Olga Yajuk, Batya Isaacson, Jawad Abed, Naseem Maalouf, Aviram Nissan, Judith Sandbank, Einav Yehuda-Shnaidman, Falk Ponath, Jörg Vogel, Ofer Mandelboim, Zvi Granot, Ravid Straussman, Gilad Bachrach
RESUMEN

Fusobacterium nucleatum is an oral anaerobe recently found to be prevalent in human colorectal cancer (CRC) where it is associated with poor treatment outcome. In mice, hematogenous F. nucleatum can colonize CRC tissue using its lectin Fap2, which attaches to tumor-displayed Gal-GalNAc. Here, we show that Gal-GalNAc levels increase as human breast cancer progresses, and that occurrence of F. nucleatum gDNA in breast cancer samples correlates with high Gal-GalNAc levels. We demonstrate Fap2-dependent binding of the bacterium to breast cancer samples, which is inhibited by GalNAc. Intravascularly inoculated Fap2-expressing F. nucleatum ATCC 23726 specifically colonize mice mammary tumors, whereas Fap2-deficient bacteria are impaired in tumor colonization. Inoculation with F. nucleatum suppresses accumulation of tumor infiltrating T cells and promotes tumor growth and metastatic progression, the latter two of which can be counteracted by antibiotic treatment. Thus, targeting F. nucleatum or Fap2 might be beneficial during treatment of breast cancer.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
5R-PLEX beads, for PCR purification